Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26081050 | 0.83 | CYP3A4 (0.43) | USP2TSHR | |
| SCHEMBL10192218 | 0.83 | FPR2 (0.48) | USP2TSHRSLC6A4SLC6A3 | |
| SCHEMBL10192232 | 0.83 | FPR2 (0.48) | USP2TSHRSLC6A4SLC6A3 | |
| SCHEMBL19030449 | 0.83 | GRIN2B (0.42) | KDM4ESMN1; SMN2TRPA1GRIN2BHTR2A | |
| SCHEMBL7296016 | 0.83 | GRIN2B (0.42) | KDM4ESMN1; SMN2TRPA1GRIN2BHTR2A | |
| Hydrochloric Acid SCHEMBL14840535 | 0.82 | GRIN2B (0.41) | KDM4ESMN1; SMN2TRPA1GRIN2BHTR2A | |
| SCHEMBL26081072 | 0.81 | KDM4E (0.49) | KDM4ESMN1; SMN2TRPA1HTR2AMEN1 | |
| SCHEMBL26081049 | 0.80 | RORC (0.38) | TRPA1HTR2AUSP2TSHR | |
| SCHEMBL28240932 | 0.79 | GRIN2B (0.43) | KDM4ESMN1; SMN2TRPA1GRIN2BHTR2A | |
| SCHEMBL10192225 | 0.79 | ALDH1A1 (0.44) | GRIN2BMEN1KMT2AIDO1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | KDM4E 1884/4885SMN1; SMN2 431/4885TRPA1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.